Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Annual Dividend Rate
Price/Cash Flow (TTM)